Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity
This article critically evaluates the Medicines and Healthcare products Regulatory Agency’s announcement, in March 2008, that GlaxoSmithKline would not face prosecution for deliberately withholding trial data, which revealed not only that Seroxat was ineffective at treating childhood depression but...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
2008
|